A Combination of Ipilimumab and Fotemustine for Treat Unresectable Locally Advanced or Metastatic Melanoma (NIBIT-M1)

Clinical Trial ID NCT01654692

Rank	Title	Journal	Year	PubWeight™‹?›
1	Improved survival with ipilimumab in patients with metastatic melanoma.	N Engl J Med	2010	67.34
2	Ipilimumab plus dacarbazine for previously untreated metastatic melanoma.	N Engl J Med	2011	26.90
3	Ipilimumab in patients with melanoma and brain metastases: an open-label, phase 2 trial.	Lancet Oncol	2012	5.32
4	Fotemustine compared with dacarbazine in patients with disseminated malignant melanoma: a phase III study.	J Clin Oncol	2004	3.97
5	Ipilimumab and fotemustine in patients with advanced melanoma (NIBIT-M1): an open-label, single-arm phase 2 trial.	Lancet Oncol	2012	2.03
6	At the bedside: CTLA-4- and PD-1-blocking antibodies in cancer immunotherapy.	J Leukoc Biol	2013	1.90
7	CTLA-4 blockade in tumor models: an overview of preclinical and translational research.	Cancer Immun	2013	1.71
8	Clinical impact of checkpoint inhibitors as novel cancer therapies.	Drugs	2014	0.99
9	Three-year follow-up of advanced melanoma patients who received ipilimumab plus fotemustine in the Italian Network for Tumor Biotherapy (NIBIT)-M1 phase II study.	Ann Oncol	2014	0.91
10	Advances in personalized targeted treatment of metastatic melanoma and non-invasive tumor monitoring.	Front Oncol	2013	0.89
11	The role of checkpoints in the treatment of GBM.	J Neurooncol	2015	0.75